Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

Supervivència lliure de progressió; Tumors neuroendocrins

Detalles Bibliográficos
Autores: Grenader, Tal, Pavel, Marianne E., Ruszniewski, Philippe B., Ćwikła, Jarosław B., Phan, Alexandria T., Raderer, Markus, Capdevila Castillon, Jaume
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/6483
Acceso en línea:https://hdl.handle.net/11351/6483
http://hdl.handle.net/11351/6483
Access Level:acceso abierto
Palabra clave:Tumors neuroendocrins - Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
id ES_ac0aec8b4516dfa43fb9aafd96b483f2
oai_identifier_str oai:recercat.cat:11351/6483
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
title Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
spellingShingle Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Grenader, Tal
Tumors neuroendocrins - Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
title_short Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
title_full Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
title_fullStr Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
title_full_unstemmed Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
title_sort Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
dc.creator.none.fl_str_mv Grenader, Tal
Pavel, Marianne E.
Ruszniewski, Philippe B.
Ćwikła, Jarosław B.
Phan, Alexandria T.
Raderer, Markus
Capdevila Castillon, Jaume
author Grenader, Tal
author_facet Grenader, Tal
Pavel, Marianne E.
Ruszniewski, Philippe B.
Ćwikła, Jarosław B.
Phan, Alexandria T.
Raderer, Markus
Capdevila Castillon, Jaume
author_role author
author2 Pavel, Marianne E.
Ruszniewski, Philippe B.
Ćwikła, Jarosław B.
Phan, Alexandria T.
Raderer, Markus
Capdevila Castillon, Jaume
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Grenader T] Oncology Institute, Leumit Health Services, Jerusalem, Israel. [Pavel ME] Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité University Medicine Berlin, Berlin, Germany. Department of Endocrinology, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, Germany. [Ruszniewski PB] Department of Gastroenterology-Pancreatology, Beaujon Hospital, Clichy, France. [Ćwikła JB] Department of Radiology, University of Varmia and Masuria, Olsztyn, Poland. [Phan AT] Hematology, Oncology & Radiation Oncology, University of Texas Health Science Center at Tyler, Tyler, Texas, USA. [Raderer M] Department of Oncology, University Hospital, Vienna, Austria. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Tumors neuroendocrins - Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
topic Tumors neuroendocrins - Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
description Supervivència lliure de progressió; Tumors neuroendocrins
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/6483
http://hdl.handle.net/11351/6483
url https://hdl.handle.net/11351/6483
http://hdl.handle.net/11351/6483
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Anti-Cancer Drugs;31(3)
https://doi.org/10.1097/CAD.0000000000000909
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wolters Kluwer Health
publisher.none.fl_str_mv Wolters Kluwer Health
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416321322582016
spelling Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumorsGrenader, TalPavel, Marianne E.Ruszniewski, Philippe B.Ćwikła, Jarosław B.Phan, Alexandria T.Raderer, MarkusCapdevila Castillon, JaumeTumors neuroendocrins - PrognosiDISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine TumorsANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::PrognosisENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinosTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronósticoSupervivència lliure de progressió; Tumors neuroendocrinsSupervivencia libre de progresión; Tumores neuroendocrinosProgression-free survival; Neuroendocrine tumorsAccessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs. In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1–2, Ki-67 < 10%). The exploratory post-hoc analyses presented here evaluated the prognostic value of NLR in the CLARINET study cohort, in the context of and independently from treatment. Kaplan–Meier PFS plots were generated for patients with available NLR data, in subgroups based on NLR values, and 24-month survival rates were calculated. P values and hazard ratios for prognostic effects were generated using Cox models. 31216222 Baseline characteristics were balanced between lanreotide autogel/depot 120 mg (n = 100) and placebo (n = 101) arms. Irrespective of treatment, raw 24-month PFS rates were comparable across subgroups based on NLR tertiles [37.3% (low), 38.8% (middle), 38.8% (high); n = 67 per group] and NLR cutoff of 4 [38.1% (NLR ≤ 4; n = 176), 40.0% (NLR > 4; n = 25)]. Furthermore, NLRs were not prognostic in Cox models, irrespective of subgroups used. The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1). These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs. This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.The CLARINET study was sponsored by Ipsen, the manufacturer of lanreotide autogel/depot. Medical writing services were provided by Nicky French PhD of Watermeadow Medical (Macclesfield, UK) – an Ashfield Company, part of UDG Healthcare plc – sponsored by Ipsen Ltd, Slough, UK in accordance with Good Publication Practice guidelines.Wolters Kluwer HealthInstitut Català de la Salut[Grenader T] Oncology Institute, Leumit Health Services, Jerusalem, Israel. [Pavel ME] Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité University Medicine Berlin, Berlin, Germany. Department of Endocrinology, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, Germany. [Ruszniewski PB] Department of Gastroenterology-Pancreatology, Beaujon Hospital, Clichy, France. [Ćwikła JB] Department of Radiology, University of Varmia and Masuria, Olsztyn, Poland. [Phan AT] Hematology, Oncology & Radiation Oncology, University of Texas Health Science Center at Tyler, Tyler, Texas, USA. [Raderer M] Department of Oncology, University Hospital, Vienna, Austria. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202120212020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/6483http://hdl.handle.net/11351/6483Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAnti-Cancer Drugs;31(3)https://doi.org/10.1097/CAD.0000000000000909Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/64832026-05-29T05:05:01Z
score 15,812429

Similares en LA Referencia